Clinical Trial Update: Study of Efficacy of a Vasopressin 2 Receptor Antagonist M0002 for Treatment of Ascites in Cirrhotic Subjects With Hypo- or Normonatraemia [Phase 2]

View source ↗

Summary

Phase 2 study assessing the efficacy of the vasopressin V2 receptor antagonist M0002 for treating ascites in cirrhotic patients with hypo- or normonatremia. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis

Drugs mentioned

• M0002 (vasopressin V2 receptor antagonist)

Snippet

Sponsor: Movetis | Conditions: Cirrhotic Ascites | Phase 2 | Status: COMPLETED